Thierry Virolle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Thierry Virolle has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Laurent Turchi
CNRS, INSERM, Institut de Biologie Valrose, Team INSERM “Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity”, Université Côte D’Azur, 06107 Nice, France
52 shared publications - Marie-Luce Vignais
CNRS, INSERM, Institut de Génomique Fonctionnelle, IGF, Université de Montpellier, 34090 Montpellier, France
52 shared publications - Adel Boughlita
Institute for Regenerative Medicine and Biotherapy, University of Montpellier, INSERM, CHU Montpellier, Montpellier, France
50 shared publications - Amélie Darlix
Department of Medical Oncology, Institut Régional du Cancer de Montpellier, University of Montpellier , Montpellier
50 shared publications - Anne-Marie Rodriguez
Université Paris-Est Créteil, INSERM, IMRB, 94010 Créteil, France
50 shared publications - Daouda Abba Moussa
University of Montpellier, INSERM, CNRS
50 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Human cortico-vascular assembloids reveal a CELF2-AHNAK-dependent switch from neuronal to endothelial tropism in glioblastoma cells
Glioblastoma (GBM) remains one of the most aggressive human cancers, driven by cellular plasticity and dynamic interactions with the neurovascular niche. Yet, further refinement of existing preclinical models is needed to improve the reproduction of the human brain–vascular interface and facilitate the study of tumor-host crosstalk and invasion. To address this limitation, we developed a human induced pluripotent stem cell (hiPSC)-derived cortico-endothelial (CO + EO) assembloid model by fusing cortical and endothelial organoids. These assembloids spontaneously form branched vascular networks enriched in tight junction proteins (CLDN5, OCLN, ZO-1), thereby recapitulating key BBB-like features and providing a physiologically relevant human platform to investigate GBM–neurovascular interactions. Using this system, we uncovered a previously unrecognized CELF2-dependent glioma stem cell (GSC) tropism. CELF2-expressing GSCs preferentially infiltrate neural regions, where they induce neuronal apoptosis and disrupt endothelial tight junction structure, supporting an aggressive phenotype. In contrast, CELF2-deficient GSCs lose neurotropism, acquire mesenchymal features, and are redirected toward vascular compartments. This endothelial affinity depends on the scaffold protein AHNAK, strongly expressed at the plasma membrane of CELF2-deficient cells and enriched at tumor-endothelial interfaces. AHNAK knockdown partially abolishes endothelial infiltration, demonstrating its role in GBM vascular tropism. Moreover, analysis of patient GBM specimens confirmed that CELF2-positive tumor cells are enriched in poorly vascularized, mitotically active regions and are largely excluded from vessel-rich zones, closely resembling the behavior observed in assembloids. Transcriptomic profiling further revealed that CELF2 promotes a neuronal progenitor-like program while repressing mesenchymal and vascular-associated gene signatures, thereby shaping tumor identity, invasive behavior, and tissue preference. Collectively, this study establishes CO + EO assembloids as an original human model of GBM plasticity at the neurovascular interface. We identify CELF2 as a master regulator of GSC tropism and AHNAK as a mediator of vascular affinity, revealing a molecular axis that governs GBM invasion and providing potential avenues for future therapeutic intervention.
- 5 August 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessHuman cortico-vascular assembloids reveal a CELF2-AHNAK-dependent switch from neuronal to endothelial tropism in glioblastoma cells
Glioblastoma (GBM) remains one of the most aggressive human cancers, driven by cellular plasticity and dynamic interactions with the neurovascular niche. Yet, further refinement of existing preclinical models is needed to improve the reproduction of the human brain–vascular interface and facilitate the study of tumor-host crosstalk and invasion. To address this limitation, we developed a human induced pluripotent stem cell (hiPSC)-derived cortico-endothelial (CO + EO) assembloid model by fusing cortical and endothelial organoids. These assembloids spontaneously form branched vascular networks enriched in tight junction proteins (CLDN5, OCLN, ZO-1), thereby recapitulating key BBB-like features and providing a physiologically relevant human platform to investigate GBM–neurovascular interactions. Using this system, we uncovered a previously unrecognized CELF2-dependent glioma stem cell (GSC) tropism. CELF2-expressing GSCs preferentially infiltrate neural regions, where they induce neuronal apoptosis and disrupt endothelial tight junction structure, supporting an aggressive phenotype. In contrast, CELF2-deficient GSCs lose neurotropism, acquire mesenchymal features, and are redirected toward vascular compartments. This endothelial affinity depends on the scaffold protein AHNAK, strongly expressed at the plasma membrane of CELF2-deficient cells and enriched at tumor-endothelial interfaces. AHNAK knockdown partially abolishes endothelial infiltration, demonstrating its role in GBM vascular tropism. Moreover, analysis of patient GBM specimens confirmed that CELF2-positive tumor cells are enriched in poorly vascularized, mitotically active regions and are largely excluded from vessel-rich zones, closely resembling the behavior observed in assembloids. Transcriptomic profiling further revealed that CELF2 promotes a neuronal progenitor-like program while repressing mesenchymal and vascular-associated gene signatures, thereby shaping tumor identity, invasive behavior, and tissue preference. Collectively, this study establishes CO + EO assembloids as an original human model of GBM plasticity at the neurovascular interface. We identify CELF2 as a master regulator of GSC tropism and AHNAK as a mediator of vascular affinity, revealing a molecular axis that governs GBM invasion and providing potential avenues for future therapeutic intervention.
- Open Access
- 24 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (23) , 16697
Identification of Metabolomic Markers in Frozen or Formalin-Fixed and Paraffin-Embedded Samples of Diffuse Glioma from Adults
The aim of this study was to identify metabolomic signatures associated with the gliomagenesis pathway (IDH-mutant or IDH-wt) and tumor grade of diffuse gliomas (DGs) according to the 2021 WHO classification on frozen samples and to evaluate the diagnostic performances of these signatures in tumor samples that are formalin-fixed and paraffin-embedded (FFPE). An untargeted metabolomic study was performed using liquid chromatography/mass spectrometry on a cohort of 213 DG samples. Logistic regression with LASSO penalization was used on the frozen samples to build classification models in order to identify IDH-mutant vs. IDH-wildtype DG and high-grade vs low-grade DG samples. 2-Hydroxyglutarate (2HG) was a metabolite of interest to predict IDH mutational status and aminoadipic acid (AAA) and guanidinoacetic acid (GAA) were significantly associated with grade. The diagnostic performances of the models were 82.6% AUC, 70.6% sensitivity and 80.4% specificity for 2HG to predict IDH status and 84.7% AUC, 78.1% sensitivity and 73.4% specificity for AAA and GAA to predict grade from FFPE samples. Thus, this study showed that AAA and GAA are two novel metabolites of interest in DG and that metabolomic data can be useful in the classification of DG, both in frozen and FFPE samples.
- 24 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (23) , 16697
Open AccessIdentification of Metabolomic Markers in Frozen or Formalin-Fixed and Paraffin-Embedded Samples of Diffuse Glioma from Adults
The aim of this study was to identify metabolomic signatures associated with the gliomagenesis pathway (IDH-mutant or IDH-wt) and tumor grade of diffuse gliomas (DGs) according to the 2021 WHO classification on frozen samples and to evaluate the diagnostic performances of these signatures in tumor samples that are formalin-fixed and paraffin-embedded (FFPE). An untargeted metabolomic study was performed using liquid chromatography/mass spectrometry on a cohort of 213 DG samples. Logistic regression with LASSO penalization was used on the frozen samples to build classification models in order to identify IDH-mutant vs. IDH-wildtype DG and high-grade vs low-grade DG samples. 2-Hydroxyglutarate (2HG) was a metabolite of interest to predict IDH mutational status and aminoadipic acid (AAA) and guanidinoacetic acid (GAA) were significantly associated with grade. The diagnostic performances of the models were 82.6% AUC, 70.6% sensitivity and 80.4% specificity for 2HG to predict IDH status and 84.7% AUC, 78.1% sensitivity and 73.4% specificity for AAA and GAA to predict grade from FFPE samples. Thus, this study showed that AAA and GAA are two novel metabolites of interest in DG and that metabolomic data can be useful in the classification of DG, both in frozen and FFPE samples.
- Open Access
CELF2 Sustains a Proliferating/OLIG2+ Glioblastoma Cell Phenotype via the Epigenetic Repression of SOX3
Glioblastomas (GBs) are incurable brain tumors. The persistence of aggressive stem-like tumor cells after cytotoxic treatments compromises therapeutic efficacy, leading to GBM recurrence. Forcing the GBM cells to irreversibly abandon their aggressive stem-like phenotype may offer an alternative to conventional cytotoxic treatments. Here, we show that the RNA binding protein CELF2 is strongly expressed in mitotic and OLIG2-positive GBM cells, while it is downregulated in differentiated and non-mitotic cells by miR-199a-3p, exemplifying GBM intra-tumor heterogeneity. Using patient-derived cells and human GBM samples, we demonstrate that CELF2 plays a key role in maintaining the proliferative/OLIG2 cell phenotype with clonal and tumorigenic properties. Indeed, we show that CELF2 deficiency in patient-derived GSCs drastically reduced tumor growth in the brains of nude mice. We further show that CELF2 promotes TRIM28 and G9a expression, which drive a H3K9me3 epigenetic profile responsible for the silencing of the SOX3 gene. Thus, CELF2, which is positively correlated with OLIG2 and Ki67 expression in human GBM samples, is inversely correlated with SOX3 and miR-199a-3p. Accordingly, the invalidation of SOX3 in CELF2-deficient patient-derived cells rescued proliferation and OLIG2 expression. Finally, patients expressing SOX3 above the median level of expression tend to have a longer life expectancy. CELF2 is therefore a crucial target for the malignant potential of GBM and warrants attention when developing novel anticancer strategies.
Open AccessCELF2 Sustains a Proliferating/OLIG2+ Glioblastoma Cell Phenotype via the Epigenetic Repression of SOX3
Glioblastomas (GBs) are incurable brain tumors. The persistence of aggressive stem-like tumor cells after cytotoxic treatments compromises therapeutic efficacy, leading to GBM recurrence. Forcing the GBM cells to irreversibly abandon their aggressive stem-like phenotype may offer an alternative to conventional cytotoxic treatments. Here, we show that the RNA binding protein CELF2 is strongly expressed in mitotic and OLIG2-positive GBM cells, while it is downregulated in differentiated and non-mitotic cells by miR-199a-3p, exemplifying GBM intra-tumor heterogeneity. Using patient-derived cells and human GBM samples, we demonstrate that CELF2 plays a key role in maintaining the proliferative/OLIG2 cell phenotype with clonal and tumorigenic properties. Indeed, we show that CELF2 deficiency in patient-derived GSCs drastically reduced tumor growth in the brains of nude mice. We further show that CELF2 promotes TRIM28 and G9a expression, which drive a H3K9me3 epigenetic profile responsible for the silencing of the SOX3 gene. Thus, CELF2, which is positively correlated with OLIG2 and Ki67 expression in human GBM samples, is inversely correlated with SOX3 and miR-199a-3p. Accordingly, the invalidation of SOX3 in CELF2-deficient patient-derived cells rescued proliferation and OLIG2 expression. Finally, patients expressing SOX3 above the median level of expression tend to have a longer life expectancy. CELF2 is therefore a crucial target for the malignant potential of GBM and warrants attention when developing novel anticancer strategies.
- Open Access
- 14 June 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring
Metabolites produced by GSCs following MSC mitochondria acquisition and TMZ treatment
- 14 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring
Metabolites produced by GSCs following MSC mitochondria acquisition and TMZ treatment
- Open Access
- 14 June 2023
- Published by American Association for Cancer Research (AACR)
Figure S6 from Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring
Metabolite detection in resected GBM from 8 patients, at 1rst resection and at 2nd resection post-TMZ treatment. For each metabolite, the C12/C13 ratios normalized to tissue protein concentrations are indicated.
- 14 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring
Metabolite detection in resected GBM from 8 patients, at 1rst resection and at 2nd resection post-TMZ treatment. For each metabolite, the C12/C13 ratios normalized to tissue protein concentrations are indicated.
- Open Access
- 14 June 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 6 from Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring
MSC mitochondria induce a higher orotate turnover in GSCs which supports resistance to TMZ. A and B, [U-13C]-glucose and [U-13C]-glutamine orotate isotope profiling in GSCs with and/or without MSC mitochondria and treated or not with TMZ (48 hours; n = 3). Mean + SEM. Statistical analysis by Student t test. ***, P < 0.001. C, Schematic of BRQ inhibition of DHODH-dependent orotate production (BioRender). D, Effect of BRQ (100 nmol/L) on the survival of GSCs (GB4 and GB5, from 2 donors) to TMZ treatment (50 μmol/L) following acquisition of MSC mitochondria (3 MSC donors for each GSC). Two-way ANOVA, *, P < 0.05; **, P < 0.01; ***, P < 0.001; n = 4, each dot represents a culture well.
- 14 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 6 from Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring
MSC mitochondria induce a higher orotate turnover in GSCs which supports resistance to TMZ. A and B, [U-13C]-glucose and [U-13C]-glutamine orotate isotope profiling in GSCs with and/or without MSC mitochondria and treated or not with TMZ (48 hours; n = 3). Mean + SEM. Statistical analysis by Student t test. ***, P < 0.001. C, Schematic of BRQ inhibition of DHODH-dependent orotate production (BioRender). D, Effect of BRQ (100 nmol/L) on the survival of GSCs (GB4 and GB5, from 2 donors) to TMZ treatment (50 μmol/L) following acquisition of MSC mitochondria (3 MSC donors for each GSC). Two-way ANOVA, *, P < 0.05; **, P < 0.01; ***, P < 0.001; n = 4, each dot represents a culture well.
- Open Access
- 14 June 2023
- Published by American Association for Cancer Research (AACR)
Video 1 from Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring
Cocultures of red MitoTracker-labeled MSCs and green CellTracker-labeled GSCs
- 14 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessVideo 1 from Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring
Cocultures of red MitoTracker-labeled MSCs and green CellTracker-labeled GSCs
- Open Access
- 14 June 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring
Effects of MSC mitochondria on GSCs metabolic response to TMZ (A, B) GSC mitochondrial mass and ROS production. FACS analysis of MitoTracker and MitoSox-labeled GSCs after the acquisition of MSC mitochondria and TMZ treatment (24 hr). (A) Mitochondrial mass. (B) ROS production. (A, B) Representative experiments and relative MFI values (mean ± SEM; n=3). One-way ANOVA, *p < 0.05. (C) Expression of Cytochrome c oxidase IV (COX IV). Representative Western blot with the corresponding membrane (MW markers in kDa) as shown in Fig. 3H.
- 14 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring
Effects of MSC mitochondria on GSCs metabolic response to TMZ (A, B) GSC mitochondrial mass and ROS production. FACS analysis of MitoTracker and MitoSox-labeled GSCs after the acquisition of MSC mitochondria and TMZ treatment (24 hr). (A) Mitochondrial mass. (B) ROS production. (A, B) Representative experiments and relative MFI values (mean ± SEM; n=3). One-way ANOVA, *p < 0.05. (C) Expression of Cytochrome c oxidase IV (COX IV). Representative Western blot with the corresponding membrane (MW markers in kDa) as shown in Fig. 3H.
- Open Access
- 14 June 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 5 from Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring
MSC mitochondria modify metabolite fluxes in GSCs. [U-13C]-glucose and [U-13C]-glutamine isotope profiling of GSCs with and/or without MSC mitochondria and treated or not with TMZ (48 hours; n = 3). A, Glycolysis intermediates. B, Isotopologues of TCA cycle metabolites from 13C-glucose (24 and 48 hours). C, Isotopologues of TCA cycle metabolites from 13C-glutamine (48 hours). M3/M4 and M5/M3 ratios of isotopologues in GSCs with/out MSC mitochondria. Mean + SEM. Two-tailed unpaired t tests; ***, P < 0.001. Colors refer to the number of carbon originating from [U-13C]-glucose (A, B) and [U-13C]-glutamine (C).
- 14 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 5 from Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring
MSC mitochondria modify metabolite fluxes in GSCs. [U-13C]-glucose and [U-13C]-glutamine isotope profiling of GSCs with and/or without MSC mitochondria and treated or not with TMZ (48 hours; n = 3). A, Glycolysis intermediates. B, Isotopologues of TCA cycle metabolites from 13C-glucose (24 and 48 hours). C, Isotopologues of TCA cycle metabolites from 13C-glutamine (48 hours). M3/M4 and M5/M3 ratios of isotopologues in GSCs with/out MSC mitochondria. Mean + SEM. Two-tailed unpaired t tests; ***, P < 0.001. Colors refer to the number of carbon originating from [U-13C]-glucose (A, B) and [U-13C]-glutamine (C).